These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 8543488

  • 1. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
    Hamacher J, Vogel F, Lichey J, Kohl FV, Diwok K, Wendel H, Lode H.
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488
    [Abstract] [Full Text] [Related]

  • 2. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
    Geroulanos SJ.
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
    Garau J, Blanquer J, Cobo L, Corcia S, Daguerre M, de Latorre FJ, León C, Del Nogal F, Net A, Rello J.
    Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
    [Abstract] [Full Text] [Related]

  • 8. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
    Basoli A, Meli EZ, Mazzocchi P, Speranza V.
    Scand J Infect Dis; 1997 Nov; 29(5):503-8. PubMed ID: 9435041
    [Abstract] [Full Text] [Related]

  • 9. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
    Shah PM, Heller A, Fuhr HG, Walther F, Halir S, Schaumann R, Böhme A, Jung B, Köhler A, Lips-Schulte C, Stille W.
    Infection; 1996 Nov; 24(6):480-4. PubMed ID: 9007599
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
    Cox CE, Holloway WJ, Geckler RW.
    Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
    Zanetti G, Harbarth SJ, Trampuz A, Ganeo M, Mosimann F, Chautemps R, Morel P, Lew D, Zimmerli W, Lange J, Glauser M.
    Int J Antimicrob Agents; 1999 Feb; 11(2):107-13. PubMed ID: 10221413
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Carbapenems in serious infections: a risk-benefit assessment.
    Norrby SR.
    Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.